Literature DB >> 18586029

Analysis of Npl4 deletion mutants in mammalian cells unravels new Ufd1-interacting motifs and suggests a regulatory role of Npl4 in ERAD.

Agnieszka Lass1, Elizabeth McConnell, Krista Fleck, Alla Palamarchuk, Cezary Wójcik.   

Abstract

Npl4 is a 67 kDa protein forming a stable heterodimer with Ufd1, which in turn binds the ubiquitous p97/VCP ATPase. According to a widely accepted model, VCP(Ufd1-Npl4) promotes the retrotranslocation of emerging ER proteins, their ubiquitination by associated ligases, and handling to the 26S proteasome for degradation in a process known as ERAD (ER-associated degradation). Using a series of Npl4 deletion mutants we have revealed that the binding of Ufd1 to Npl4 is mediated by two regions: a conserved stretch of amino acids from 113 to 255 within the zf-Npl4 domain and by the Npl4 homology domain between amino acids 263 and 344. Within the first region, we have identified two discrete subdomains: one involved in Ufd1 binding and one regulating VCP binding. Expression of any one of the mutants failed to induce any changes in the morphology of the ER or Golgi compartments. Moreover, we have observed that overexpression of all the analyzed mutants induced mild ER stress, as evidenced by increased Grp74/BiP expression without associated XBP1 splicing or induction of apoptosis. Surprisingly, we have not observed any accumulation of the typical ERAD substrate alphaTCR. This favors the model where the Ufd1-Npl4 dimer forms a regulatory gate at the exit from the retrotranslocone, rather than actively promoting retrotranslocation like the p97VCP ATPase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586029     DOI: 10.1016/j.yexcr.2008.06.008

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  A non-canonical role of the p97 complex in RIG-I antiviral signaling.

Authors:  Qian Hao; Shi Jiao; Zhubing Shi; Chuanchuan Li; Xia Meng; Zhen Zhang; Yanyan Wang; Xiaomin Song; Wenjia Wang; Rongguang Zhang; Yun Zhao; Catherine C L Wong; Zhaocai Zhou
Journal:  EMBO J       Date:  2015-10-15       Impact factor: 11.598

2.  Disulfiram combats cancer via crippling valosin-containing protein/p97 segregase adaptor NPL4.

Authors:  Nan Ding; Qianzheng Zhu
Journal:  Transl Cancer Res       Date:  2018-04       Impact factor: 1.241

3.  The tissue-specific Rep8/UBXD6 tethers p97 to the endoplasmic reticulum membrane for degradation of misfolded proteins.

Authors:  Louise Madsen; Franziska Kriegenburg; Andrea Vala; Diana Best; Søren Prag; Kay Hofmann; Michael Seeger; Ian R Adams; Rasmus Hartmann-Petersen
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

4.  Upregulation of NPL4 promotes bladder cancer cell proliferation by inhibiting DXO destabilization of cyclin D1 mRNA.

Authors:  Bao-Sai Lu; Yue-Wei Yin; Yan-Ping Zhang; Ping-Ying Guo; Wei Li; Kai-Long Liu
Journal:  Cancer Cell Int       Date:  2019-05-30       Impact factor: 5.722

5.  Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias.

Authors:  Daniel L Sun; Soumya Poddar; Roy D Pan; Ethan W Rosser; Evan R Abt; Juno Van Valkenburgh; Thuc M Le; Vincent Lok; Selena P Hernandez; Janet Song; Joanna Li; Aneta Turlik; Xiaohong Chen; Chi-An Cheng; Wei Chen; Christine E Mona; Andreea D Stuparu; Laurent Vergnes; Karen Reue; Robert Damoiseaux; Jeffrey I Zink; Johannes Czernin; Timothy R Donahue; Kendall N Houk; Michael E Jung; Caius G Radu
Journal:  RSC Med Chem       Date:  2020-02-24

6.  ATP binding to p97/VCP D1 domain regulates selective recruitment of adaptors to its proximal N-domain.

Authors:  Wei Sheng Chia; Diana Xueqi Chia; Feng Rao; Shoshana Bar Nun; Susana Geifman Shochat
Journal:  PLoS One       Date:  2012-12-03       Impact factor: 3.240

7.  Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.

Authors:  Zdenek Skrott; Martin Mistrik; Klaus Kaae Andersen; Søren Friis; Dusana Majera; Jan Gursky; Tomas Ozdian; Jirina Bartkova; Zsofia Turi; Pavel Moudry; Marianne Kraus; Martina Michalova; Jana Vaclavkova; Petr Dzubak; Ivo Vrobel; Pavla Pouckova; Jindrich Sedlacek; Andrea Miklovicova; Anne Kutt; Jing Li; Jana Mattova; Christoph Driessen; Q Ping Dou; Jørgen Olsen; Marian Hajduch; Boris Cvek; Raymond J Deshaies; Jiri Bartek
Journal:  Nature       Date:  2017-12-06       Impact factor: 49.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.